Upfront Diagnostics and Vingmed Group Partner to Bring Innovative Stroke Diagnostic Technology Across the Nordic Region

Partnership aims to serve the stroke-affected population across Sweden, Denmark, Finland, Norway and beyond with over 100,000 stroke alerts per year.

We are pleased to announce a strategic partnership between Upfront Diagnostics, a UK-based MedTech company dedicated to transforming stroke care through innovative diagnostic solutions, and the Vingmed Group, a leading distributor of advanced medical equipment in the Nordic region.

Upfront Diagnostics has developed LVOne, the world's first rapid blood test designed to help identify large vessel occlusion (LVO) strokes at the point of care within minutes and improve triage decisions in the pre-hospital setting. Using innovative biomarkers, emergency teams are enabled to rapidly assess patients and identify those most likely to benefit from specialist interventions, reduce delays to treatment and consequently improve outcomes for patients experiencing acute neurological emergencies.

By combining Upfront Diagnostics' technological innovation with Vingmed Group's market expertise and distribution capabilities, this partnership will accelerate access to advanced healthcare solutions across the Nordic region.

The collaboration also strengthens Vingmed's offering within emergency and acute care diagnostics, enabling healthcare professionals to access innovative technologies that can contribute to clinical decision-making and improved patient pathways.

"We are proud to partner with Upfront Diagnostics and add LVOne to our portfolio of innovative acute care solutions. This collaboration strengthens our commitment to providing healthcare professionals with technologies that support faster clinical decision-making and improved patient care, particularly in time-critical conditions such as stroke," said Kolbjørn Haarr, CEO, Vingmed Group.

"We are thrilled to bring LVOne to patients across the Nordics, and proud to do so alongside Vingmed, a leading name in medical device distribution. This is a hugely important partnership for us, and a major step towards making rapid stroke diagnosis a standard of care worldwide," said Gonzalo Ladreda, CEO and Co-founder, Upfront Diagnostics.

Under the agreement, Vingmed will serve as the authorised distributor for LVOne. The partnership is designed to decentralise stroke testing and reduce time to thrombectomy, bringing specialist-level triage capability closer to the patient at the earliest possible stage of care.

This partnership with Vingmed forms part of Upfront Diagnostics' broader EU distribution strategy, supporting the global commercialisation of LVOne and the company's mission to make rapid, decentralised stroke diagnosis a standard of care.

About Upfront Diagnostics: Founded in Cambridge in 2017, Upfront Diagnostics is a MedTech company focused on developing and commercialising rapid point-of-care diagnostic tests for time-critical medical conditions. The company's flagship product, LVOne, is a blood-based diagnostic test designed to support early identification of severe stroke. Using innovative biomarkers, Upfront Diagnostics is enabling emergency teams to rapidly assess patients and identify those most likely to benefit from specialist interventions. The company is ISO 13485 certified and aims to reduce delays to treatment and improve outcomes for patients experiencing acute neurological emergencies.

For further information:
Ritesh S, Communications & Marketing Specialist
Upfront Diagnostics
ritesh@upfrontdiagnostics.com

About Vingmed Group: The Vingmed Group, founded in 1968, is a leading Nordic distributor of advanced medical technology. With operations in Norway, Sweden, Denmark and Finland, Vingmed provides innovative medical solutions to healthcare professionals. The company is ISO 9001, ISO 14001, ISO 13485 and ISO 27001 certified.

For further information www.vingmed.com, info@vingmed.com